+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Atherosclerosis Drugs Market by Drug Class (Anti-Hypertensive Drugs, Antiplatelet Agents, Cholesterol-lowering Drugs), Route of Administration (Injectable, Oral), Disease Stage, Distribution Channel - Forecast 2024-2030- Product Image
Global Atherosclerosis Drugs Market by Drug Class (Anti-Hypertensive Drugs, Antiplatelet Agents, Cholesterol-lowering Drugs), Route of Administration (Injectable, Oral), Disease Stage, Distribution Channel - Forecast 2024-2030- Product Image
Sale

Global Atherosclerosis Drugs Market by Drug Class (Anti-Hypertensive Drugs, Antiplatelet Agents, Cholesterol-lowering Drugs), Route of Administration (Injectable, Oral), Disease Stage, Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967871
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Atherosclerosis Drugs Market size was estimated at USD 22.59 billion in 2023, USD 23.82 billion in 2024, and is expected to grow at a CAGR of 5.66% to reach USD 33.23 billion by 2030.

Atherosclerosis drugs refer to a variety of medications designed to slow or reverse the buildup of plaque in the arteries, a condition known as atherosclerosis. This buildup can lead to heart disease, stroke, and other cardiovascular issues. The major factors contributing to the expansion of their use include the rising prevalence of cardiovascular diseases globally, increased awareness and diagnosis rates, advancements in drug development, and a growing aging population at higher risk of developing atherosclerosis. However, these drugs are not without their challenges, such as potential side effects, varying efficacy among individuals, and the high cost of treatment, particularly with newer, patent-protected medications.

Addressing these issues requires ongoing research to develop more effective and safer medications, implement strategies to reduce healthcare costs, and improve patient education on lifestyle changes that can complement drug therapy. Biotechnology advancements and personalized medicine approach that tailor treatment to the individual's genetic makeup is expected to diversify the opportunities for the improved development of atherosclerosis drugs.

Regional Insights

The Americas showcases significant atherosclerosis drug development, backed by robust R&D infrastructure, significant healthcare expenditure, and a strong presence of leading pharmaceutical companies. This region benefits from advanced healthcare frameworks and favorable government policies promoting drug innovation and quick adoption. Conversely, the APAC region, led by countries such as China, Japan, and India, is experiencing rapid growth in the atherosclerosis drugs market. This surge is powered by increasing healthcare awareness, rising cardiovascular disease prevalence, and improving healthcare infrastructures.

However, APAC's market is more fragmented with a mix of local and international players, and there is a rising focus on generic drug production due to cost sensitivity in the region. On the other hand, EMEA presents a mature market scenario with stringent regulatory standards and a strong emphasis on drug efficacy and safety. The European Union's unified regulatory framework under the European Medicines Agency (EMA) facilitates a streamlined process for drug approval across member states yet poses challenging market entry barriers for new players. The Middle East and Africa segment of EMEA, while smaller in market size, is gradually expanding, owing to increasing investment in healthcare infrastructure and a growing focus on chronic disease management.

Market Trends by Segment

  • Drug Class: High adoption of cholesterol-lowering drugs for general atherosclerosis treatment
  • Distribution Channel: Improved availability of atherosclerosis drugs through online channels

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

NIH Awards The Texas Heart Institute USD 1.14 Million To Develop A Novel Drug For Atherosclerotic Cardiovascular Disease

The National Heart, Lung, and Blood Institute (NHLBI) bestowed a grant of USD 1.14 million upon The Texas Heart Institute® (THI) for an initiative over the span of two years. This funding aims to support the development of an innovative, premiere drug designed to enhance the treatment landscape for cardiovascular disease (CVD), with a particular focus on mitigating complications associated with atherosclerosis. This endeavor marks a significant stride towards advancing therapeutic options and improving outcomes for individuals grappling with the ramifications of this prevalent condition.

US FDA Approves Expanded Indication For Novartis Leqvio (inclisiran) For Adults With High LDL-C

The US Food and Drug Administration (FDA) approved an important label update for Novartis's Leqvio (inclisiran), now allowing its earlier application in managing elevated LDL-cholesterol (LDL-C) levels among patients at heightened heart disease risk, alongside diet and statin therapy. The recent modification broadens its indication to include patients with primary hyperlipidemia, fostering its application beyond the confines of atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH).

Anti-Inflammatory Drug for Cardiovascular Disease Approved by FDA

The U.S. Food and Drug Administration (FDA) granted approval to Lodoco (colchicine) for reducing the likelihood of myocardial infarction, stroke, coronary revascularization, and cardiovascular mortality among adults. This milestone gives Agepha Pharma the accolade of creating the inaugural medication specifically designed to mitigate the inflammation associated with atherosclerotic cardiovascular disease. Thus, Lodoco emerges as a therapeutic advance and a beacon of hope for enhancing the quality of life for individuals grappling with atherosclerotic cardiovascular diseases.

Key Company Profiles

The report delves into recent significant developments in the Atherosclerosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agepha Pharma US, Amgen Inc., Anthos Therapeutics, Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cardurion Pharmaceuticals, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc., NewAmsterdam Pharma, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, and Verve Therapeutics.

This research report offers invaluable insights into various crucial aspects of the Atherosclerosis Drugs Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of CVDs and atherosclerosis diseases
5.1.1.2. Initiatives promoting diagnosis and early treatment of heart diseases
5.1.2. Restraints
5.1.2.1. Risk of recalls of atherosclerosis drugs
5.1.3. Opportunities
5.1.3.1. Ongoing research projects for introducing advanced atherosclerosis drugs
5.1.3.2. Rising government approvals for atherosclerosis drugs
5.1.4. Challenges
5.1.4.1. Complications of new atherosclerosis drug development
5.2. Market Segmentation Analysis
5.2.1. Drug Class: High adoption of cholesterol-lowering drugs for general atherosclerosis treatment
5.2.2. Distribution Channel: Improved availability of atherosclerosis drugs through online channels
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Atherosclerosis Drugs Market, by Drug Class
6.1. Introduction
6.2. Anti-Hypertensive Drugs
6.3. Antiplatelet Agents
6.4. Cholesterol-lowering Drugs
7. Atherosclerosis Drugs Market, by Route of Administration
7.1. Introduction
7.2. Injectable
7.3. Oral
8. Atherosclerosis Drugs Market, by Disease Stage
8.1. Introduction
8.2. Atheroma Formation
8.3. Atherosclerotic Plaques Formation
8.4. Fatty Streaks Formation
9. Atherosclerosis Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Americas Atherosclerosis Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Atherosclerosis Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Atherosclerosis Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. NIH Awards The Texas Heart Institute USD 1.14 Million To Develop A Novel Drug For Atherosclerotic Cardiovascular Disease
13.3.2. US FDA Approves Expanded Indication For Novartis Leqvio (inclisiran) For Adults With High LDL-C
13.3.3. Anti-Inflammatory Drug for Cardiovascular Disease Approved by FDA
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. ATHEROSCLEROSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ATHEROSCLEROSIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ATHEROSCLEROSIS DRUGS MARKET DYNAMICS
FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ATHEROSCLEROSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVE DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVE DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROMA FORMATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROMA FORMATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROSCLEROTIC PLAQUES FORMATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROSCLEROTIC PLAQUES FORMATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FATTY STREAKS FORMATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FATTY STREAKS FORMATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 49. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 50. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 51. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 52. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 53. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 54. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 55. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 56. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 57. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 58. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 59. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 60. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 61. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 62. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 63. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 64. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 65. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 66. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 67. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 68. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 69. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 70. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 71. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 72. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 73. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 74. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 75. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 76. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 77. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 78. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 79. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 80. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 81. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 82. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 83. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 84. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 85. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 86. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 87. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 88. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 90. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 92. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 94. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 96. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 98. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 99. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 100. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 101. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 102. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 103. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 104. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 105. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 106. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 107. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 108. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 109. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 110. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 111. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 112. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 113. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 114. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 115. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 116. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 117. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 118. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 119. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 120. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 121. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 122. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 123. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 124. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 125. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 126. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 127. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 128. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 129. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 130. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 131. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 132. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 133. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 134. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 135. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 136. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 137. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 138. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 139. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 140. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 141. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 142. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 143. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 144. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 145. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 146. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 147. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 148. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 149. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 150. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 151. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 152. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 153. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 154. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 155. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 156. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 157. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 158. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 159. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 160. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 161. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 162. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 163. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 164. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 165. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 166. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 167. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 168. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 169. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 170. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 171. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 172. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 173. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 174. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 175. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 176. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 177. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 178. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 179. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 180. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 181. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 182. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 183. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 184. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 185. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 186. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 187. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 188. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 189. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 190. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 191. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 192. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 193. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 194. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 205. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 206. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 207. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 208. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 209. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 210. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 211. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 212. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 213. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 214. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 215. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 216. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 217. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 218. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 219. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 220. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 221. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 222. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 223. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 224. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 225. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 226. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 227. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 228. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 229. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 230. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 231. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 232. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 233. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 234. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 235. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 236. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 237. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 238. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 239. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 240. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 241. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 242. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 243. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 244. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 245. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 246. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 247. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 248. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 249. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 250. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 251. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 252. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 253. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 254. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 255. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 256. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 257. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 258. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 259. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 260. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 261. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 262. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 263. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 264. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 265. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 266. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 267. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 268. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 269. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 270. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 271. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 272. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 273. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 274. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 275. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 276. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 277. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 278. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 279. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 280. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 281. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 282. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 283. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 284. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 285. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 286. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 287. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 288. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 289. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 290. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 291. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 292. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 293. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 294. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 295. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 296. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 297. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 298. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 299. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 300. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 301. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 302. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 303. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 304. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 305. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 306. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 307. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 308. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 310. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 312. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 314. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 316. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 318. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 320. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
TABLE 322. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 324. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 325. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
TABLE 326. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MIL

Companies Mentioned

  • Abbott Laboratories
  • Agepha Pharma US
  • Amgen Inc.
  • Anthos Therapeutics
  • Artery Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cardurion Pharmaceuticals
  • CSL Behring
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • NewAmsterdam Pharma
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Verve Therapeutics

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 23.82 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.23 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Atherosclerosis Drugs Global Market Report 2024 - Product Image

Atherosclerosis Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 183 Pages
  • Global
From
Global Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report by Drug Class (Diuretics, ACE Inhibitors), Type (Primary, Secondary), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report by Drug Class (Diuretics, ACE Inhibitors), Type (Primary, Secondary), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 180 Pages
  • Global
From
Global Cholesterol Lowering Drug Market by Disease Type (Cardiovascular Diseases, Hypercholesterolemia, Hyperlipidemia), Class of Drug (Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations), Distribution Channels - Forecast 2024-2030 - Product Image

Global Cholesterol Lowering Drug Market by Disease Type (Cardiovascular Diseases, Hypercholesterolemia, Hyperlipidemia), Class of Drug (Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations), Distribution Channels - Forecast 2024-2030

  • Report
  • 190 Pages
  • Global
From
Cholesterol Lowering Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032 - Product Image

Cholesterol Lowering Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032

  • Report
  • 173 Pages
  • Global
From

About the Atherosclerosis Drug Market

Atherosclerosis is a condition in which the arteries become hardened and narrowed due to the buildup of plaque. Atherosclerosis drugs are used to treat this condition and are a major component of the cardiovascular drug market. These drugs are used to reduce the risk of heart attack, stroke, and other cardiovascular diseases. Commonly used drugs include statins, antiplatelet drugs, and fibrates. Statins are used to reduce cholesterol levels, while antiplatelet drugs are used to prevent blood clots. Fibrates are used to reduce triglyceride levels. In addition to these drugs, lifestyle changes such as diet and exercise are also important in treating atherosclerosis. These changes can help reduce the risk of cardiovascular disease and improve overall health. Companies in the Atherosclerosis Drug market include Pfizer, Merck, Sanofi, AstraZeneca, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.